IRCCS MultiMedica - Prevention of cardiovascular diseases

Abstract

IRCCS MultiMedica - Prevention of cardiovascular diseases
Physiopathology, translational research and experimental applications

This special issue is centered on the cardiovascular research at MultiMedica; The current research focuses on understanding the molecular and clinical mechanisms underlying atherosclerosis and related cardiometabolic disorders, with the ultimate goal of improving prevention, diagnosis, and treatment. Our work integrates basic, translational, and clinical research, ranging from studies on lipid metabolism, inflammation, and genetic risk factors to large-scale clinical investigations and registries.
A strong emphasis is placed on innovative therapeutic strategies, including lipid-lowering therapies, novel biomarkers, and emerging technologies such as omics and precision medicine. Collaboration across disciplines—cardiology, diabetology, nephrology, and molecular biology—ensures a comprehensive approach to cardiovascular disease, while partnerships at the national and international level strengthen our impact on patient care and scientific advancement.

Editorial
Alberico L. Catapano
EAJ 2025;Special Issue;1

PCSK9 in extrahepatic tissues: What can we expect from its inhibition?
Angela Pirillo, Lale Tokgözoglu, Alberico Luigi Catapano
EAJ 2023;2:35-43

Is there still a place for fenofibrate-statin combination therapy?
Michel Farnier, Michal Vrablik, Alberico Luigi Catapano
EAJ 2023;3:44-49

Role of nuclear medicine assessing patients with suspected coronary artery disease
Roberto F.E. Pedretti, Luca Genovese, Luca Alberti, Alessandro Cecilia, Martina Cellamare, Matteo Crippa, Gianmarco Dacquino, Aurora Danza, Matteo Della Torre, Federico Ferrari Bravo, Giuseppe Galati, Francesco Torlone, Simona Sarzi Braga
EAJ 2024;1:4-6

BPIFB4 protein and monocyte phenotyping: a preclinical asset for marking the frailty condition
Elena Ciaglia, Silvana Mirella Aliberti, Francesco Montella, Valentina Lopardo, Albino Carrizzo, Paola Di Pietro, Cristina Basile, Anna Maciag, Maria Consiglia Calabrese, Mario Capunzo, Carmine Vecchione, Annibale Alessandro Puca
EAJ 2024;1:7-16

Effect of anti-PCSK9 drugs on the association of PCSK9 to LDL
Sara Matteucci, Valentina Pravatà, Francesco Maria Esposito, Angela Pirillo, Liliana Grigore, Alberico L. Catapano
EAJ 2024;1:17-20

MicroRNAs in the progression of atherosclerosis: rise and fall of the atherosclerotic plaque
Andrea Rampin, Martina Mutoli, Massimiliano Martelli, Alberto M. Settembrini, Fabio Martelli, Tijana Mitic, Miron Sopic, Antonino Bruno, Gaia Spinetti, AtheroNET COST Action CA21153
EAJ 2024;2:38-50

Atherosclerosis and cholesterol: What we should know
Alberico L. Catapano
EAJ 2024;2:54-56

Atherosclerotic cardiovascular disease and measurement of lipoprotein(a) levels in Italy
Elena Olmastroni, Manuela Casula, Sining Xie, Alberico L. Catapano
EAJ 2024;3:67-72